This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
NSE NIFTY 50 Constituent
|Founder||Khwaja Abdul Hamied|
|Headquarters||Mumbai, Maharashtra, India|
|Products||Pharmaceuticals and diagnostics|
|Revenue||₹21,760 crore (US$2.7 billion) (2022)|
|₹3,496.05 crore (US$440 million) (2022)|
|₹2,516.75 crore (US$320 million) (2022)|
|Total assets||₹23,662.56 crore (US$3.0 billion) (2020)|
|Total equity||₹15,763.00 crore (US$2.0 billion) (2020)|
Number of employees
Cipla Limited (stylized as Cipla) is an Indian multinational pharmaceutical company, headquartered in Mumbai. Cipla primarily develops medicines to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and many other medical conditions.
Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third largest drug producer in India.
In 1935, Cipla was founded by Khwaja Abdul Hamied as 'The Chemical, Industrial & Pharmaceutical Laboratories' in Mumbai. In July 1984, the name of the company was changed to 'Cipla Limited'.
In 1985, the US FDA approved the company's bulk drug against HIV and other drugs to treat poor people in the developing world. Led by the founder's son Yusuf Hamied, a Cambridge-educated chemist, the company provided generic AIDS and other drugs to treat poor people in the developing world. In 1995, Cipla launched Deferiprone, the world's first oral iron chelator. In 2001, Cipla offered antiretrovirals for HIV treatment at a fractional cost (less than $350 per year per patient).
In 2013 Cipla acquired the South African company Cipla-Medpro, kept it as a subsidiary, and changed its name to Cipla Medpro South Africa Limited. At the time of the acquisition, Cipla-Medpro had been a distribution partner for Cipla and was South Africa's third-biggest pharmaceutical company. The company had been founded in 2002 and was known as Enaleni Pharmaceuticals Ltd. In 2005, Enaleni bought all the shares of Cipla-Medpro, which had been a joint venture between Cipla and Medpro Pharmaceuticals, a South African generics company, and in 2008 it changed its name to Cipla-Medpro.
In September 2015, Cipla acquired InvaGen Pharmaceuticals and Exelan Pharmaceuticals, two American pharmaceutical companies, for 555 million dollars.
In 2015, Cipla incorporated Cipla Health Limited as a wholly-owned subsidiary to focus on the consumer healthcare business that includes over-the-counter (OTC) and prescription products. The company has a strong portfolio of brands including ActivKids, Cofsils, Cheston, Clocip, Maxirich, Nicotex, Omnigel, Naselin, Prolyte ORS, and MamaXpert. Cipla Health is committed to providing high-quality, affordable healthcare products to consumers in India and around the world. The company is one of the leading players in the consumer healthcare market in India and is focused on growing the business through innovation and expansion.
In 2019 Cipla entered digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa.
Products and services
Cipla sells active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products, including escitalopram oxalate (anti-depressant), lamivudine, and fluticasone propionate. They are the world's largest manufacturer of antiretroviral drugs.
In July 2020, the company announced the introduction of Gilead Sciences' Remdesivir under the brand name CIPREMI in India after reaching a voluntary licensing agreement with parent company and DCGI approval for "restricted emergency use" in COVID-19 treatment of critical confirmed patients.
Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80 countries. Exports accounted for 48% ₹4,948 crore (equivalent to ₹71 billion or US$890 million in 2020) of its revenue for FY 2013–14. Cipla spent ₹517 crore (5.4% of their revenue) in FY 2013–14 on R&D activities. The primary focus areas for R&D were development of new formulations, drug-delivery systems and APIs (active pharmaceutical ingredients). Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.
As on 31 March 2013, the company had 22,036 employees (out of which 2,455 were women (7.30%) and 23 were employees with disabilities (0.1%)). During the FY 2013–14, the company incurred ₹1,285 crore (equivalent to ₹17 billion or US$220 million in 2020) on employee benefit expenses.
The equity shares of Cipla are listed on the Bombay Stock Exchange, where it is a constituent of the BSE SENSEX index, and the National Stock Exchange of India, where it is a constituent of the CNX Nifty. Its Global Depository Receipts (GDRs) are listed on the Luxembourg Stock Exchange.
As of 31 December 2022, the promoter group, Y. K. Hamied and his family, hold around 33.61% equity shares in Cipla. Individual shareholders hold approximately 14.72% of its shares. SBI Mutual Fund, LIC etc. are the largest non-promoter shareholders in the Company.
|Shareholders (as on 31-December-2022)||Shareholding|
|Foreign Institutional Investors (FII)||28.39%|
Awards and recognitions
- In 2012, Cipla received the Thomson Reuters India Innovation Award.
- Cipla won Dun & Bradstreet American Express Corporate Awards in 2006.
- In 2007, Forbes included Cipla in the 200 'Best under a billion' list of best small Asian companies.
- In 1980, Cipla won Chemexcil Award for Excellence for exports.
- In 2015, Cipla stood third in the India's Most Reputed Brands (Pharmaceutical) list, in a study conducted by BlueBytes, a leading Media Analytics firm in association with TRA Research, a brand insights organization (both a part of the Comniscient Group).
In August 2007, Cipla launched an emergency contraception drug "i-pill" sold over the counter, which was controversial with regard to its being available without a prescription and the large amount of drug contained per dose.
In the late 1960s, Cipla began manufacturing a new, patented drug, propranolol, without the permission of the drug's patent holder, Imperial Chemical Industries (ICI), who protested to the Indian government. The CEO of Cipla pressured the government of Indira Gandhi to change India's patent laws to eliminate patents that directly covered drugs, and instead to allow only patents that covered methods to make drugs. so that Cipla could go ahead and produce as many low-priced generic drugs for the poor as possible. Since then Cipla has also produced a low-cost drug to treat HIV, and expanded operations into several developing countries, including African nations, where most HIV and poor patients existed at one time. But the changes made led to criticism of both India's patent laws and Cipla. India reinstated patents on drugs in 2005.
- ^ a b "Cipla Consolidated Profit & Loss account, Cipla Financial Statement & Accounts". www.moneycontrol.com. Retrieved 28 July 2020.
- ^ "Cipla Consolidated Profit & Loss account, Cipla Financial Statement & Accounts". www.moneycontrol.com. Retrieved 21 June 2020.
- ^ a b "Cipla Consolidated Balance Sheet, Cipla Financial Statement & Accounts". www.moneycontrol.com. Retrieved 28 July 2020.
- ^ a b c "Business Responsibility Report 2013-14" (PDF). Cipla. 15 July 2014. Archived from the original (PDF) on 17 March 2015. Retrieved 17 September 2014.
- ^ "How a little blue pill changed Cipla's fortunes". 9 February 2014.
- ^ "Cipla betting big on digitisation and emerging segments". The Economic Times. Retrieved 6 December 2022.
- ^ "Cipla betting big on digitisation and emerging segments". Financial Express. Retrieved 6 December 2022.
- ^ a b "About us - History". Cipla Limited. Archived from the original on 27 October 2015. Retrieved 3 November 2014.
- ^ a b "Company History - Cipla Ltd". Economic Times. Retrieved 3 November 2013.
- ^ a b "Interview with Yusuf Hamied". Creating Emerging Markets. Harvard Business School.
- ^ "Indian drug company offers cheap AIDS drugs". USA Today. 19 June 2001. Retrieved 3 November 2013.
- ^ a b Jawani, Lohit (16 July 2013). "Cipla completes acquisition of South Africa's Cipla Medpro". VC Circle. Archived from the original on 15 March 2016. Retrieved 8 September 2016.
- ^ "Delists from JSE". Business Day Live. 2013. Retrieved 13 July 2013.
- ^ "Enaleni Pharmaceuticals Limited Prospectus 2005". Morningstar. Retrieved 8 September 2016.
- ^ Avafia, Tenu; Berger, Jonathan; Hartzenberg, Trudi (2006). "The ability of select sub-Saharan African countries to utilise TRIPs Flexibilities and Competition Law to ensure a sustainable supply of essential medicines: A study of producing and importing countries" (PDF). WHO. Archived from the original (PDF) on 23 January 2014.
- ^ Kahn, Tamar (10 September 2008). "South Africa: Enaleni Takes Name of Its Unit Cipla-Medpro". All Africa.
- ^ JARVIS, LISA (4 September 2006). "Mylan Will Buy Most of Matrix". Chemical & Engineering News Archive. 84 (36): 8. doi:10.1021/cen-v084n036.p008. ISSN 0009-2347.
- ^ "Cipla's History". Cipla South Africa. n.d. Retrieved 16 May 2022.
- ^ a b "cipla ltd (CIPLA:Natl India)". Business Week. Archived from the original on 6 November 2013. Retrieved 7 November 2013.
- ^ "AIDS Healthcare Foundation Campaign Challenges Cipla Over Drug Pricing in India" (Press release). PR Newswire. 8 August 2007. Retrieved 4 November 2013.
- ^ "India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug". Reuters. 21 June 2020.
- ^ "Coronavirus drug: Cipla launches Cipremi's, claims it is the cheapest Remdesivir". The Financial Express. 9 July 2020.
- ^ "Coronavirus drug: Cipla ramps up production of antiviral remdesivir amid demand spurt". businesstoday.in.
- ^ "Corporate Information: At a Glance". Cipla. Archived from the original on 12 September 2016. Retrieved 6 July 2019.
- ^ "Cipla in the pink of health". Business Standard. 25 September 2013. Retrieved 5 November 2013.
- ^ a b c d "Annual Report 2013-14" (PDF). Cipla. 22 August 2014. Archived from the original (PDF) on 22 January 2015. Retrieved 17 September 2014.
- ^ "Cipla Limited". BSEindia.com. Retrieved 2 November 2013.
- ^ "Scripwise Weightages in S&P BSE SENSEX". BSE India. Archived from the original on 1 December 2015. Retrieved 2 November 2013.
- ^ "NTPC Limited". NSE India. Retrieved 2 November 2013.
- ^ "Download List of CNX Nifty stocks (.csv)". NSE India. Retrieved 2 November 2013.
- ^ "StockEdge". web.stockedge.com. Retrieved 25 January 2023.
- ^ "Trang chủ qh88". Retrieved 10 May 2023.
- ^ "Latest CIPLA Shareholding Pattern". Equitymaster. Retrieved 25 January 2023.
- ^ DBT, Cipla get Thomson Reuters India innovation awards
- ^ "Pharmaceutical sector award". Dun & Bradstreet. 10 September 2006. Archived from the original on 4 November 2013. Retrieved 3 November 2013.
- ^ "Asian Paints, Cipla in Forbes list". Economic Times. 17 November 2005. Retrieved 3 November 2013.
- ^ "Company Profile - Cipla Limited". IndiaInfoline.com. Retrieved 3 November 2013.
- ^ "Lupin, Sun Pharma and Cipla amongst tops most reputed pharma brand list". The Economic Times. timesofindia.com. 17 August 2016. Retrieved 6 July 2019.
- ^ "Home". bluebytes.info.
- ^ "Home". trustadvisory.info.
- ^ "Cipla rises on morning-after pill". Hindustan Times. 5 October 2007. Archived from the original on 5 February 2015. Retrieved 3 November 2013.
- ^ "Cipla Launches i-pill". Financial Express. Retrieved 3 November 2013.
- ^ "'i-pill' by Cipla draws criticism from experts". Financial Express. 27 October 2007. Retrieved 3 November 2013.
- ^ a b "The Treasure of Mumbai". Wired Magazine. December 2006. Retrieved 4 November 2013.
- ^ "Heart-warming story of the Hamieds, who set up CIPLA and have been saving lives". National Herald. April 2020. Retrieved 12 April 2020.
- ^ "Indian Generic Drug Maker Targets Sad Americans". biohealthinvestor.com. 3 January 2007. Retrieved 4 November 2013.